Impact: Controlling plasma tHcy levels is unlikely to favorably modify adenoma recurrence risk in folate-fortified populations. Cancer Epidemiol Biomarkers Prev; 19(10); 2541–8. ©2010 AACR.
and all studies involved subjects with relatively low folate intake. Thus, it is not clear whether the association between plasma tHcy and colorectal neoplasia is independent of folate availability or whether the association is still present when plasma tHcy is in the lower range. Plasma tHcy was not associated with colorectal cancer risk in three more recent studies (19-21).

In the current study we assessed the association between plasma tHcy and subsequent colorectal adenoma recurrence risk in subjects who were randomized to receive either a 1 mg/day folic acid supplement or a placebo for up to three years. In our study population, subjects were randomized and followed during a period of increasing folic acid intake in the source population, during which time the mean plasma tHcy levels in the study population decreased. We sought to assess how any associations with baseline plasma tHcy were modified by folic acid treatment assignment. We hypothesized that if plasma tHcy was a risk marker for adenoma recurrence it would be evident only in the placebo group, which maintained higher mean plasma tHcy levels during follow-up than those in the folic acid group in which plasma tHcy remained uniformly low.

Materials and Methods

Design
These data were collected as part of a randomized, double-blind, placebo-controlled trial of the efficacy of oral aspirin (ASA), folic acid, or both to prevent colorectal adenomas as described (22, 23). Briefly, this was a three-by-two factorial design in which subjects were randomized to receive either 81 mg/day ASA, 325 mg/day ASA, or placebo. Within each ASA/placebo group, subjects were additionally randomized to receive 1 mg supplemental folic acid/day or a placebo. The study initially focused only on aspirin; 100 subjects who were randomized only to aspirin were not included in this analysis.

Recruitment, randomization, treatment, and follow-up
Details of subject eligibility, recruitment, randomization, treatment, and follow-up, and study outcomes have been described (22, 23). Briefly, subjects were recruited from July 1994 until March 1998 from nine clinical centers. Eligible subjects were between 21 and 80 years of age, in good health, and had received a recommendation for a 3-year follow-up colonoscopy by their regular medical practitioner. Each eligible subject met at least one of the following three criteria: (a) one or more histologically confirmed colorectal adenomas removed within three months of their recruitment; (b) one or more histologically confirmed adenomas removed within 16 months of their enrollment as well as a history of two or more confirmed adenomas; or (c) an adenoma >1 cm in diameter. Individuals were ineligible if they had a history compatible with a familial colorectal cancer syndrome, invasive colorectal cancer, any malabsorption syndrome, a medical condition that could be worsened by use of aspirin or folic acid, or any medical condition commonly treated with aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or folate. Before entering the trial all subjects were required to have had a complete colonoscopy with removal of all polyps within three months of their entry into the trial. Each subject underwent a three-month run-in period on 325 mg ASA prior to randomization into ASA and folic acid treatment groups. Only subjects with ≥80% compliance and no other contraindications were randomized. By protocol, all subjects had an anticipated follow-up complete surveillance colonoscopy 34 to 40 months after the qualifying examination.

In the initial study design, subjects in each treatment group were followed for three years and adenoma recurrence was determined at the end of that three-year follow-up interval (the first follow-up). Due to concern that a longer follow-up interval might be necessary to observe the effect of folic acid supplementation, subjects were invited to remain on the study supplements until the next surveillance examination (typically three or five years later). The current analysis reflects plasma tHcy measurements made at study enrollment and adenomas found during the first follow-up period, i.e., through 36 to 40 months after the baseline colonoscopy. To assess the change in plasma tHcy levels over the follow-up interval, a second measurement was taken at the beginning of the second follow-up.

Study outcomes
The primary study outcome was the proportion of patients in whom one or more colorectal adenomas were detected in the period starting one year after randomization to the end of the year 3 surveillance follow-up examination. If a year-3 colonoscopy was not done, we used the last examination at least one year after randomization. Adenomas were classified as neoplastic (adenomatous) or nonneoplastic by the study pathologist, who also assessed the degree of dysplasia and the extent of villous component in each adenoma. We defined advanced lesions as invasive carcinoma or adenomas with at least 25% villous component, high-grade dysplasia, or an estimated size of ≥1 cm. Patients were considered to have “multiple adenomas” when there were a total of ≥3 follow-up adenomas by the end of the year 3 exam.

Plasma total Hcy, folate, and vitamin B2, B6, and B12 determination
Plasma tHcy and other nutrients were determined in nonfasting blood samples taken at baseline and approximately three years later. Blood samples were collected into 7-mL Vacutainer brand tubes containing EDTA. After collection, specimens were immediately put on ice and then centrifuged at 1,100 × g for 10 minutes. Whole blood, plasma, and Buffy coat fractions were stored at −80°C and then transferred to Dartmouth Medical School where they were stored at −80°C until analysis. Plasma
Plasma Homocysteine and Adenoma Recurrence

The MTHFR genotypes, 677C>T and 1298A>C, were genotyped with the 5′-nuclease TaqMan allelic discrimination assay using the ABI7900 (Applied Biosystems). PCR primers and dual-labeled allele discrimination probes were designed using the Primer Express software package (PE Biosystems) as described by Gibson et al. (29). Each 384-well assay contained internal quality controls for homozygous wild-type, heterozygous, and homozygous variant alleles for the respective polymorphisms along with no-template controls. Genotype calls were determined by SDS 2.1 analysis software.

Statistical analysis

Statistical significance was defined as a two-sided P value ≤ 0.05. To compare those with an adenoma recurrence with those without a recurrence, we used t-tests or Wilcoxon rank-sum tests for continuous variables and χ² tests for categorical variables. The main exposure variable was quartile of baseline plasma tHcy. Baseline plasma tHcy quartiles were determined with reference to the whole study population.

In the analysis of the change in plasma tHcy over calendar time we calculated means and SD by recruitment year and estimated a P for trend using orthogonal linear contrasts and Wald tests. For the analysis of the association between plasma tHcy quartile and number of polyps at the baseline examination we used a proportional odds model, where the outcome was the number of baseline adenomas (1, 2, 3, 4 or ≥5; ref. 30). The output of this analysis can be interpreted as the odds ratio (OR) for the higher versus lower adenoma number, whatever the high/low cut point. We controlled for a priori potential confounders by adding to the model variables that have been associated with both plasma tHcy and adenoma recurrence in the literature or in the current trial population: age, cigarette smoking (never, former, current), alcohol use (continuous, as drinks/day), body mass index (BMI; continuous), plasma total folate, plasma B₁₂, plasma B₉ (as PLP), and plasma B₂ (as B₁₂, the main active form of vitamin B₂) and B₁₂ were determined in plasma by liquid chromatography-tandem mass spectrometry (27). All B-vitamin assays were conducted at the laboratory of Bevital AS, Bergen Norway.

Results

There were 1,021 subjects randomized to folic acid or placebo. A total of 871 subjects (85.0%) had baseline and follow-up plasma tHcy and provided adenoma data; 392 had one or more recurrent adenomas and 479 had no recurrent adenomas. The baseline characteristics of the study population by adenoma recurrence status are shown in Table 1. Those with an adenoma recurrence were significantly older; they were more likely to be male, have a higher BMI, and drink alcohol, and had lower plasma vitamin B₂ levels. Baseline plasma total folate was inversely associated with recurrence risk in the total study population (P = 0.013). Baseline plasma tHcy was significantly higher in those with an adenoma recurrence in the crude analysis (P = 0.04).

Baseline plasma tHcy decreased significantly over the 5-year recruitment period (P for trend < 0.001; data not shown). Mean baseline plasma tHcy was 10.7 ± 3.6 μmol/L among subjects recruited in 1995 and decreased to a mean of 8.7 ± 2.0 μmol/L among subjects recruited in 1998. By the time of the year 3 measurement mean plasma tHcy for those in the placebo group had leveled off at approximately 9.2 μmol/L (P for trend 0.142).

Table 2 shows the univariate associations between selected baseline factors and plasma tHcy. Those in the highest quartile of tHcy were older and were more likely to be male, current smokers, and alcohol drinkers. They also had a higher BMI, lower plasma folate, B₂, B₁₂, and B₉ and a higher number of adenomas at the baseline examination. Table 3 shows the association between baseline plasma tHcy and the number of adenomas at the baseline examination. There was a borderline significant
direct association between increasing plasma tHcy and the number of adenomas at the baseline examination after adjustment for age, sex, recruitment center, current smoking, BMI, and alcohol intake (\( P \) for trend = 0.06). Subjects with the highest plasma tHcy were about 50% more likely to be in a higher baseline adenoma group. The proportional OR was 1.49 (95% CI, 0.95-2.31; \( P \) for trend = 0.06). After additional control for plasma folate

### Table 1. Baseline characteristics of study subjects by adenoma recurrence

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Adenoma recurrence</th>
<th>No adenoma recurrence</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. participants</td>
<td>392 (45.0)</td>
<td>479 (55.0)</td>
<td></td>
</tr>
<tr>
<td>Mean age at baseline (SD), y</td>
<td>59.1 (9.4)</td>
<td>56.2 (9.5)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Male sex, ( n ) (%)</td>
<td>270 (68.9)</td>
<td>289 (60.3)</td>
<td>0.01†</td>
</tr>
<tr>
<td>Colorectal cancer in first-degree relative, ( n ) (%)</td>
<td>117 (37.6)</td>
<td>148 (38.1)</td>
<td>0.91‡</td>
</tr>
<tr>
<td>NSAID use at baseline, ( n ) (%)</td>
<td>319 (81.4)</td>
<td>379 (79.1)</td>
<td>0.41‡</td>
</tr>
<tr>
<td>Multivitamin use at baseline, ( n ) (%)</td>
<td>134 (34.2)</td>
<td>183 (38.2)</td>
<td>0.22‡</td>
</tr>
<tr>
<td>Race/Ethnicity, ( n ) (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>346 (88.3)</td>
<td>408 (85.2)</td>
<td>0.18‡</td>
</tr>
<tr>
<td>African American</td>
<td>23 (5.9)</td>
<td>25 (5.2)</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>16 (4.1)</td>
<td>27 (5.6)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>7 (1.8)</td>
<td>19 (4.0)</td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;25</td>
<td>104 (26.6)</td>
<td>161 (33.7)</td>
<td>0.08†</td>
</tr>
<tr>
<td>25–&lt;30</td>
<td>191 (48.9)</td>
<td>212 (44.4)</td>
<td></td>
</tr>
<tr>
<td>≥30</td>
<td>96 (24.6)</td>
<td>105 (22.0)</td>
<td></td>
</tr>
<tr>
<td>Current cigarette smoker, ( n ) (%)</td>
<td>72 (18.5)</td>
<td>51 (10.7)</td>
<td>0.00†</td>
</tr>
<tr>
<td>Mean dietary intake (SD), kcal/day</td>
<td>1,645 (697)</td>
<td>1,614 (612)</td>
<td>0.49*</td>
</tr>
<tr>
<td>Mean dietary folate intake (SD), ( \mu )g/day</td>
<td>316 (144)</td>
<td>327 (158)</td>
<td>0.31*</td>
</tr>
<tr>
<td>Mean total folate intake (SD), ( \mu )g/day</td>
<td>452 (256)</td>
<td>466 (249)</td>
<td>0.41*</td>
</tr>
<tr>
<td>Mean baseline plasma folate (SD), ( \mu )mol/L</td>
<td>22.1 (15.3)</td>
<td>25.3 (19.4)</td>
<td>0.01‡</td>
</tr>
<tr>
<td>Mean baseline plasma B[12] (SD), ( \mu )mol/L</td>
<td>322 (144)</td>
<td>337 (179)</td>
<td>0.15‡</td>
</tr>
<tr>
<td>Mean baseline plasma B[6] (SD), ( \mu )mol/L</td>
<td>77.8 (90.8)</td>
<td>84.1 (90.6)</td>
<td>0.01‡</td>
</tr>
<tr>
<td>Mean plasma Hcy at baseline (SD), ( \mu )mol/L</td>
<td>10.1 (3.1)</td>
<td>9.6 (2.8)</td>
<td>0.04‡</td>
</tr>
<tr>
<td>Alcohol use at baseline, ( n ) (%)</td>
<td>278 (72.8)</td>
<td>297 (64.7)</td>
<td>0.01†</td>
</tr>
<tr>
<td>Caffeine use at baseline, ( n ) (%)</td>
<td>366 (95.8)</td>
<td>428 (93.3)</td>
<td>0.11‡</td>
</tr>
<tr>
<td>History of high cholesterol at baseline, ( n ) (%)§</td>
<td>142 (36.3)</td>
<td>147 (30.8)</td>
<td>0.08†</td>
</tr>
<tr>
<td>History of hypertension at baseline, ( n ) (%)§</td>
<td>97 (24.7)</td>
<td>120 (25.1)</td>
<td>0.92‡</td>
</tr>
<tr>
<td>Lifetime adenomas at baseline, mean (SD)</td>
<td>2.8 (2.6)</td>
<td>2.0 (1.7)</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>Number of baseline adenomas, mean (SD)</td>
<td>1.7 (1.1)</td>
<td>1.5 (0.9)</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>Advanced adenomas at baseline, ( n ) (%)∥</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>248 (70.5)</td>
<td>315 (70.3)</td>
<td>0.97†</td>
</tr>
<tr>
<td>≥1</td>
<td>104 (29.6)</td>
<td>133 (29.7)</td>
<td></td>
</tr>
<tr>
<td><strong>MTHFR 677 C&gt;T genotype</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>178 (47.2)</td>
<td>197 (44.0)</td>
<td>0.35†</td>
</tr>
<tr>
<td>CT</td>
<td>166 (44.0)</td>
<td>199 (44.4)</td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>33 (8.8)</td>
<td>52 (11.6)</td>
<td></td>
</tr>
<tr>
<td><strong>MTHFR 1298 A&gt;C genotype</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>174 (46.0)</td>
<td>234 (52.1)</td>
<td>0.22†</td>
</tr>
<tr>
<td>AC</td>
<td>169 (44.7)</td>
<td>179 (39.9)</td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>36 (9.3)</td>
<td>36 (8.0)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: NSAID, nonsteroidal anti-inflammatory drugs.

*Two sample \( t \)-test.

† \( \chi^2 \) test.

‡Nonparametric Wilcoxon rank sum test.

§Self-reported from the risk factor questionnaire.

∥Advanced adenoma was defined as a \( \geq 25\% \) villous component, large adenoma (\( \geq 1 \) cm), advanced dysplasia, carcinoma \textit{in situ}, or invasive cancer.
and vitamins B2, B6, and B12 the adjusted proportional OR was attenuated at 1.18 (95% CI, 0.74-1.86; P for trend = 0.43).

Table 4 shows the association between baseline plasma tHcy and subsequent adenoma risk after stratifying on folic acid treatment group. The quartile 4/quartile 1 adjusted RRs were 0.98 (95% CI, 0.70-1.38; P for trend = 0.17) and 0.81 (95% CI, 0.58-1.12; P for trend = 0.17) in the placebo and supplemented groups, respectively (P for heterogeneity between treatment groups = 0.53). There was also no material difference in the RRs for advanced lesions (Table 4). There was no modification of RRs for either end point by sex, aspirin treatment group, or MTHFR 677C>T genotype (data not shown).

**Discussion**

In this analysis of subjects participating in a randomized clinical trial of folate and/or aspirin for the prevention of colorectal adenomas there was no association between baseline plasma tHcy and adenoma recurrence risk in either the placebo or the folic acid supplementation groups. The lack of association between plasma tHcy and recurrence risk was similar for all adenoma end points. Baseline plasma tHcy was associated with the number of adenomas at the baseline examination, but this association was attenuated and no longer statistically significant after controlling for potential confounders, including plasma total folate and other B vitamins.
Homocysteine is formed from SAH, a product of transmethylation reactions using S-adenosylmethionine (SAM) as methyl donor. Hcy can be remethylated to methionine or, alternatively, irreversibly transsulfurated to cystathionine by the vitamin B6-dependent enzyme cystathionine-β-synthase. Any Hcy that is not remethylated or converted to cystathionine is rapidly exported to plasma where it can be measured as a combination of related protein-bound thiols and free Hcy, referred to as plasma total Hcy (plasma tHcy; ref. 31).

Plasma tHcy has been suggested to be a direct measure of intracellular methylation capacity (11, 13, 32) due to its equilibrium with SAH, a potent inhibitor of SAM-dependent methylation reactions. In the study by Yi et al. (13) the relationship between plasma tHcy and SAH seemed to be linear for plasma tHcy values from 5 to 18 μmol/L, suggesting a positive association even for very low values of plasma tHcy. That this association may be functionally relevant is suggested by several studies that have reported significantly less global DNA methylation in circulating lymphocytes or colorectal epithelium in those with higher plasma tHcy (13, 17, 33), and in human umbilical vein endothelial cells (32). However, none of the human studies have shown this association to be independent of plasma folate levels. Plasma tHcy may also be associated with increased DNA damage. Fenech et al. (15) reported that plasma tHcy >10 μmol/L was associated with increased numbers of micronuclei in circulating lymphocytes, an association independent of circulating folate. Additionally, plasma tHcy is a potentially more inclusive marker of compromised one-carbon metabolism than is plasma folate alone because of its association with B vitamins other than folate (1-4), as well as the MTHFR 677C>T genotype (5-8). In one study plasma tHcy was a more sensitive index of colonic mucosal folate than was plasma folate (34).

Previous studies of the association between plasma tHcy and risk of colorectal neoplasia have had mixed results. Four studies reported increased risk of colorectal cancer (12, 16-18), colorectal adenomas (17), or adenoma recurrence (12) for those with higher plasma tHcy. However, the increase was statistically significant in only two of these studies (12, 18) and only one (12) controlled for plasma folate. Our results are concordant with those of three other recent studies that did not observe a significant increase in colorectal cancer risk with increasing plasma tHcy (19-21).

We did not observe any association between plasma tHcy and adenoma recurrence even among subjects assigned to placebo. About half the subjects in our study were recruited after voluntary folate fortification of the U.S. food supply began in 1996, and the first 3-year observation period overlapped a time of gradually increasing folic acid availability in U.S. and Canadian diets, with consequently decreasing tHcy levels. It is possible that our negative results are due to the progressively lower plasma tHcy, which may have fallen to levels below a threshold for an association with adenoma risk. In this regard, it is of interest that one of the studies that did not find an association of tHcy with colorectal cancer risk (19) relied on blood samples collected from 2001 to 2006, after fortification of grain products with folic acid, as in the current study. However, this would not explain the null results of two other studies (20, 21) that involved nonfortified European populations with comparatively higher plasma tHcy levels.

Plasma tHcy levels were highest at the baseline examination. The number of adenomas at the baseline...
examination was significantly associated with baseline plasma tHcy in univariate analysis. When we pursued this finding further, we found that after controlling for other plasma tHcy determinants (e.g., plasma folate and other B vitamins) the association between baseline plasma tHcy and adenomas was substantially attenuated and no longer statistically significant. This suggests that even at the higher plasma tHcy levels at the baseline examination there was little independent effect of plasma tHcy in this study population.

This study has several limitations, including the requirement that all subjects in the study cohort have at least one adenoma before randomization, a design feature that limits the generalizability of our results, and the progressively higher folate levels our study subjects experienced over the period of follow-up, even for those randomized to placebo. We were not able to control for serum creatinine, a well-known determinant of plasma tHcy. However, we do not think this affected the main result of no association between plasma tHcy and adenoma recurrence because creatinine is not a risk factor for either adenoma occurrence or recurrence and therefore is not likely to be a confounder by definition. For the analysis of the association of baseline plasma tHcy and the number of baseline adenomas we would not expect confounding a priori but in the worst case scenario, where increased serum creatinine is positively associated with baseline adenoma number as well as higher plasma tHcy, the bias would be away from the null toward an increased risk for multiple adenomas in those with higher plasma tHcy as we saw in the minimally adjusted model. However, our results were null in the fully adjusted model, suggesting that this was not a major source of confounding in the final analysis. Additionally, because baseline plasma tHcy was measured after the occurrence of prior adenomas we cannot exclude the possibility that the presence of adenomas affected baseline plasma tHcy, although this seems unlikely.

The advantages of our study include the large sample size and the high follow-up rate for subjects. Additionally, we had data on many known determinants of plasma tHcy and could control for them in our analysis. Finally, because of the prospective design and the fact that all subjects were cleared of polyps at their baseline exam, we were able to assess the effect of baseline plasma tHcy on incident as well as prevalent adenomas.

In summary, we did not see an association between higher baseline plasma tHcy and adenoma recurrence risk in this prospective study of folate and aspirin supplementation. These results do not support those of some earlier studies, which suggested that plasma tHcy may be a marker for increased risk of colorectal cancer, adenoma, and adenoma recurrence at higher plasma tHcy values, but are concordant with three other studies that did not observe any association between plasma tHcy and colorectal cancer risk. Our data suggest one of two possibilities: that there is no independent association between plasma tHcy and adenoma recurrence risk or that any association between plasma tHcy and adenoma recurrence may be limited to plasma tHcy levels higher than those characterizing the current, largely folic acid-fortified, study population.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank all the individuals who participated in this clinical trial.

Grant Support

National Cancer Institute, National Institutes of Health under CA059005 and CA100971.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 05/19/2010; revised 07/14/2010; accepted 07/20/2010; published OnlineFirst 09/14/2010.

References


Baseline Plasma Total Homocysteine and Adenoma Recurrence: Results from a Double Blind Randomized Clinical Trial of Aspirin and Folate Supplementation

A. Joan Levine, Maria V. Grau, Leila A. Mott, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-10-0536

Cited articles
This article cites 32 articles, 22 of which you can access for free at:
http://cebp.aacrjournals.org/content/19/10/2541.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/19/10/2541.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.